Cerebral palsy (CP) is a group of neurological disorders that primarily affect movement, muscle tone, posture, and balance due to abnormal brain development or damage to the developing brain, typically occurring before, during, or shortly after birth. It is the most common motor disability in childhood, affecting approximately 18 million people worldwide[3]. The global prevalence of CP varies but is generally estimated to range from 1.5 to 4 per 1000 live births, with some regions like India reporting slightly higher rates between 2.08 and 3.88 per 1000 live births[4].
The worldwide burden of cerebral palsy is significant, not only because of the motor impairments but also due to associated comorbidities such as intellectual disabilities, epilepsy, speech and hearing impairments, scoliosis, and joint contractures. These comorbidities can severely impact the quality of life (QoL) of individuals with CP, with studies showing that 30–89% of children with CP have additional impairments depending on the type of CP[4]. The World Health Organization defines quality of life as an individual’s perception of their position in life within their cultural and value context, highlighting the importance of addressing both physical and psychosocial aspects in CP care[4].
From a market and treatment perspective, the global cerebral palsy treatment market was valued at approximately USD 3.27 billion in 2021 and is projected to grow to about USD 4.42 billion by 2030, expanding at a compound annual growth rate (CAGR) of around 3.4% from 2022 to 2030[2]. Similarly, the broader cerebral palsy market, which includes therapeutics, rehabilitation, and assistive technologies, was valued at about USD 2.79 billion in 2024 and is expected to reach nearly USD 3.79 billion by 2032, growing at a CAGR of 3.88%[1]. This growth is driven by increasing incidence rates, rising awareness, advances in telemedicine, innovative therapies including pharmacological and stem cell treatments, and greater healthcare expenditure globally[1][2].
The global CP care landscape is evolving with the integration of patient-centric rehabilitation approaches and technological innovations such as telemedicine platforms, custom orthotics, and assistive devices that enhance mobility and independence. For example, orthotic devices like ankle-foot orthoses and specialized spinal supports are tailored to individual needs, helping many people with CP lead more independent and fulfilling lives[3]. Despite the non-progressive nature of CP, symptoms and care needs change over time, requiring ongoing adaptation of treatment and support strategies.
Epidemiological data indicate that CP remains a lifelong condition with a stable prevalence worldwide, but the severity and associated disabilities vary widely. The presence of comorbidities such as epilepsy and intellectual disabilities complicates management and affects long-term outcomes. Research underscores the importance of early intervention and comprehensive care to improve motor function and quality of life[4].
In summary, cerebral palsy affects millions globally with a prevalence of roughly 1.5 to 4 per 1000 live births. The market for CP treatment and care is expanding steadily due to technological advances and increased healthcare investment. The condition’s complexity, including frequent comorbidities, necessitates multidisciplinary approaches that combine medical, rehabilitative, and assistive technologies to optimize outcomes and quality of life for individuals with CP[1][2][3][4].
—
Sources:
[1] Global Cerebral Palsy Market size to Reach USD 3.79 Billion by 2032, Global Food Industry Watch, 2025.
[2] Cerebral Palsy Treatment Market to Reach USD 4.42 Billion by 2030, Taiwan News, 2025.
[3] Celebrating World Cerebral Palsy Day 2025, PrimeCare Prosthetics, 2025.
